YTHDC1

Summary

YTHDC1 (YTH N6-methyladenosine RNA binding protein C1, HGNC:30626) is a protein-coding gene on chromosome 4q13.2, encoding YTH domain-containing protein 1 (Q96MU7). Regulator of alternative splicing that specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs. It is a selective cancer dependency (DepMap: 42.5% of cell lines).

Enables N6-methyladenosine-containing RNA reader activity and RNA binding activity. Involved in gene expression and regulation of gene expression. Located in nuclear speck and plasma membrane.

Source: NCBI Gene 91746 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autism spectrum disorder (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 82 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 42.5% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001031732

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30626
Approved symbol	YTHDC1
Name	YTH N6-methyladenosine RNA binding protein C1
Location	4q13.2
Locus type	gene with protein product
Status	Approved
Aliases	YT521, KIAA1966, YT521-B
Ensembl gene	ENSG00000083896
Ensembl biotype	protein_coding
OMIM	617283
Entrez	91746

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 10 protein_coding, 1 retained_intron

ENST00000344157, ENST00000355665, ENST00000505251, ENST00000506175, ENST00000507529, ENST00000510746, ENST00000579690, ENST00000910853, ENST00000910854, ENST00000936187, ENST00000936188

RefSeq mRNA: 3 — MANE Select: NM_001031732 NM_001031732, NM_001330698, NM_133370

CCDS: CCDS33992, CCDS3522, CCDS82929

Canonical transcript exons

ENST00000344157 — 17 exons

Exon	Start	End
ENSE00000969898	68337027	68337450
ENSE00001012548	68318826	68318862
ENSE00001012568	68316314	68316448
ENSE00001012580	68322749	68322915
ENSE00001072474	68318690	68318729
ENSE00001072476	68330002	68330119
ENSE00001072477	68333308	68333397
ENSE00001072479	68330202	68330310
ENSE00001072480	68318519	68318581
ENSE00001072482	68320123	68320205
ENSE00001072483	68332103	68332197
ENSE00001220825	68332794	68332847
ENSE00001331970	68337572	68337900
ENSE00001524098	68310387	68314323
ENSE00003578631	68338283	68338384
ENSE00003682990	68324139	68324223
ENSE00003899620	68349726	68350090

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 98.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 51.9570 / max 1004.7530, expressed in 1809 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52336	48.4219	1809
52334	1.4670	717
52335	0.8686	475
52332	0.6806	325
52337	0.5189	300

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	98.52	gold quality
corpus callosum	UBERON:0002336	98.31	gold quality
sural nerve	UBERON:0015488	97.99	gold quality
left ovary	UBERON:0002119	97.83	gold quality
ovary	UBERON:0000992	97.69	gold quality
bone marrow	UBERON:0002371	97.52	gold quality
endometrium	UBERON:0001295	97.50	gold quality
ventricular zone	UBERON:0003053	97.36	gold quality
right ovary	UBERON:0002118	97.26	gold quality
right lung	UBERON:0002167	97.10	gold quality
vagina	UBERON:0000996	97.01	gold quality
ectocervix	UBERON:0012249	97.00	gold quality
uterine cervix	UBERON:0000002	96.98	gold quality
lymph node	UBERON:0000029	96.92	gold quality
body of uterus	UBERON:0009853	96.86	gold quality
endocervix	UBERON:0000458	96.85	gold quality
body of pancreas	UBERON:0001150	96.77	gold quality
mucosa of stomach	UBERON:0001199	96.71	gold quality
zone of skin	UBERON:0000014	96.66	gold quality
skin of leg	UBERON:0001511	96.66	gold quality
ganglionic eminence	UBERON:0004023	96.65	gold quality
skin of abdomen	UBERON:0001416	96.64	gold quality
tibial nerve	UBERON:0001323	96.63	gold quality
minor salivary gland	UBERON:0001830	96.47	gold quality
saliva-secreting gland	UBERON:0001044	96.44	gold quality
thoracic mammary gland	UBERON:0005200	96.37	gold quality
subcutaneous adipose tissue	UBERON:0002190	96.30	gold quality
lower esophagus mucosa	UBERON:0035834	96.21	gold quality
esophagus mucosa	UBERON:0002469	96.20	gold quality
pancreas	UBERON:0001264	96.18	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.43

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

189 targeting YTHDC1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-8485	100.00	77.57	4731
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 42.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• YT521-B has a role in a gene expression in the pathogenesis of Emery-Dreifuss muscular dystrophy (PMID:12755701)
• phosphorylation causes sequestration of YT521-B in an insoluble nuclear form, which is unable to change splice sites (PMID:15175272)
• Lack of YT521 protein is associated with endometrial cancer. (PMID:20686370)
• Hypoxia induces a specific switch in YT521 expression pattern towards the two non-protein coding mRNA variants, the already characterized isoform 3 and the newly discovered exon 8-skipping isoform. (PMID:23765422)
• Studied mRNA levels of FOXO1, KLF9 and YT521 in human normal and cancerous endometrial tissue. A remarkable (not significant, p = 0.069) increase was found in the YT521 mRNA level of patients’ endometrial tissue in comparison with the control subjects. (PMID:23865345)
• The YTHDC1-binding sites and biochemical experiments, not only reveal the specific mode of m(6)A-YTH binding but also explain the preferential recognition of the GG(m(6)A)C sequences by YTHDC1. (PMID:25242552)
• Results show that YTHDC1 promotes exon inclusion in targeted mRNAs through recruiting pre-mRNA splicing factor SRSF3 while blocking SRSF10 mRNA binding. (PMID:26876937)
• Without proper localization of these processing factors it is difficult to establish a direct link between mRNA m6A methylation and mRNA splicing, although it is likely that YTHDC1 is mechanistically involved (PMID:27050931)
• Here, the authors show that the N(6)-methyladenosine-binding protein YTHDC1 mediates export of methylated mRNA from the nucleus to the cytoplasm in HeLa cells. (PMID:28984244)
• YTHDC1 is involved in MAT2A mRNA stability control. (PMID:29262316)
• reader of N6-methyladenosine modification in germ cell tumors (PMID:30903744)
• Modulation of circRNA Metabolism by m(6)A Modification. (PMID:32402287)
• METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation. (PMID:32615088)
• Biochemical and structural basis for YTH domain of human YTHDC1 binding to methylated adenine in DNA. (PMID:32663306)
• YTHDC1 gene polymorphisms and hepatoblastoma susceptibility in Chinese children: A seven-center case-control study. (PMID:32729171)
• Downregulation of m(6) A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non-small cell lung cancer. (PMID:32956555)
• Atomistic and Thermodynamic Analysis of N6-Methyladenosine (m(6)A) Recognition by the Reader Domain of YTHDC1. (PMID:33472367)
• YTHDC1 gene polymorphisms and Wilms tumor susceptibility in Chinese children: A five-center case-control study. (PMID:33737126)
• The RNA Binding Proteins YTHDC1 and FMRP Regulate the Nuclear Export of N(6)-Methyladenosine-Modified Hepatitis B Virus Transcripts and Affect the Viral Life Cycle. (PMID:33883220)
• N(6)-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. (PMID:34048709)
• A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication. (PMID:34255814)
• Enhancer RNA m6A methylation facilitates transcriptional condensate formation and gene activation. (PMID:34375583)
• VIRMA contributes to non-small cell lung cancer progression via N(6)-methyladenosine-dependent DAPK3 post-transcriptional modification. (PMID:34520821)
• YTHDC1 gene polymorphisms and neuroblastoma susceptibility in Chinese children. (PMID:34897032)
• Overexpression of m6A-factors METTL3, ALKBH5, and YTHDC1 alters HPV16 mRNA splicing. (PMID:35190939)
• Multiple Phosphorylations of SR Protein SRSF3 and Its Binding to m(6)A Reader YTHDC1 in Human Cells. (PMID:35563766)
• YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway. (PMID:35974388)
• Downregulation of the m[6]A reader protein YTHDC1 leads to islet beta-cell failure and diabetes. (PMID:36302453)
• Chromatin-associated YTHDC1 coordinates heat-induced reprogramming of gene expression. (PMID:36516773)
• YTHDC1 maintains trophoblasts function by promoting degradation of m6A-modified circMPP1. (PMID:36780989)
• The Effect of N6-Methyladenosine Regulators and m6A Reader YTHDC1-Mediated N6-Methyladenosine Modification Is Involved in Oxidative Stress in Human Aortic Dissection. (PMID:36819785)
• Reduction of mRNA m[6]A associates with glucose metabolism via YTHDC1 in human and mice. (PMID:36878322)
• Alternative splicing of HOXB-AS3 underlie the promoting effect of nuclear m6A reader YTHDC1 on the self-renewal of leukemic stem cells in acute myeloid leukemia. (PMID:36906205)
• N6-methyladenosine reader protein YTHDC1 regulates influenza A virus NS segment splicing and replication. (PMID:37053288)
• YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer. (PMID:37070134)
• The YTHDC1/GLUT3/RNF183 axis forms a positive feedback loop that modulates glucose metabolism and bladder cancer progression. (PMID:37258572)
• WTAP activates MAPK signaling through m6A methylation in VEGFA mRNA-mediated by YTHDC1 to promote colorectal cancer development. (PMID:37428639)
• Low expression of m6A reader YTHDC1 promotes progression of ovarian cancer via PIK3R1/STAT3/GANAB axis. (PMID:37781028)
• YTHDC1-Modified m6A Methylation of Hsa_circ_0102678 Promotes Keratinocyte Inflammation Induced by Cutibacterium acnes Biofilm through Regulating miR-146a/TRAF6 and IRAK1 Axis. (PMID:37903473)
• YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancer. (PMID:37903990)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ythdc1	ENSDARG00000051953
mus_musculus	Ythdc1	ENSMUSG00000035851
rattus_norvegicus	Ythdc1	ENSRNOG00000001996
drosophila_melanogaster	Ythdc1	FBGN0027616

Paralogs (3): YTHDF1 (ENSG00000149658), YTHDF3 (ENSG00000185728), YTHDF2 (ENSG00000198492)

Protein

Protein identifiers

YTH domain-containing protein 1 — Q96MU7 (reviewed: Q96MU7)

Alternative names: Splicing factor YT521

All UniProt accessions (5): Q96MU7, J3KRG5, J3KRW0, J3KS01, J3QR07

UniProt curated annotations — full annotation on UniProt →

Function. Regulator of alternative splicing that specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs. M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in the efficiency of mRNA splicing, processing and stability. Acts as a key regulator of exon-inclusion or exon-skipping during alternative splicing via interaction with mRNA splicing factors SRSF3 and SRSF10. Specifically binds m6A-containing mRNAs and promotes recruitment of SRSF3 to its mRNA-binding elements adjacent to m6A sites, leading to exon-inclusion during alternative splicing. In contrast, interaction with SRSF3 prevents interaction with SRSF10, a splicing factor that promotes exon skipping: this prevents SRSF10 from binding to its mRNA-binding sites close to m6A-containing regions, leading to inhibit exon skipping during alternative splicing. May also regulate alternative splice site selection. Also involved in nuclear export of m6A-containing mRNAs via interaction with SRSF3: interaction with SRSF3 facilitates m6A-containing mRNA-binding to both SRSF3 and NXF1, promoting mRNA nuclear export. Involved in S-adenosyl-L-methionine homeostasis by regulating expression of MAT2A transcripts, probably by binding m6A-containing MAT2A mRNAs. Also recognizes and binds m6A on other RNA molecules. Involved in random X inactivation mediated by Xist RNA: recognizes and binds m6A-containing Xist and promotes transcription repression activity of Xist. Also recognizes and binds m6A-containing single-stranded DNA. Involved in germline development: required for spermatogonial development in males and oocyte growth and maturation in females, probably via its role in alternative splicing. Independently of its N6-methyladenosine-containing RNA reader activity, it regulates PPARG stability by preventing its interaction with the E3 ubiquitin ligase ARIH2, thereby protecting it from ubiquitin-mediated proteasomal degradation and contributing to brown adipose tissue (BAT) development and energy homeostasis.

Subunit / interactions. Interacts with SRSF1. Interacts with SRSF2. Interacts with SRSF3. Interacts with SRSF7. Interacts with SRSF10. Interacts with CPSF6. Interacts with KHDRBS1/SAM68. Interacts with TRA2B. Interacts with KHDRBS3. Interacts with EMD. Interacts with RBMX. Interacts with ZCCHC8. Interacts (via its intrinsically disordered region) with PPARG; the interaction prevents PPARG from its ubiquitin-mediated proteasomal degradation.

Subcellular location. Nucleus. Nucleus speckle.

Post-translational modifications. Tyrosine phosphorylated.

Domain organisation. The YTH domain mediates RNA-binding.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96MU7-1	1	yes
Q96MU7-2	2

RefSeq proteins (3): NP_001026902, NP_001317627, NP_588611 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007275	YTH_domain	Domain
IPR045168	YTH_prot	Family

Pfam: PF04146

UniProt features (81 total): mutagenesis site 21, compositionally biased region 14, modified residue 13, strand 11, helix 8, region of interest 4, binding site 4, chain 1, domain 1, cross-link 1, splice variant 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

108 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
6T02	X-RAY DIFFRACTION	1.1
6YNP	X-RAY DIFFRACTION	1.1
6SZX	X-RAY DIFFRACTION	1.17
6WE8	X-RAY DIFFRACTION	1.18
6YKZ	X-RAY DIFFRACTION	1.2
6YL0	X-RAY DIFFRACTION	1.2
6YNN	X-RAY DIFFRACTION	1.2
7P8B	X-RAY DIFFRACTION	1.2
7PJQ	X-RAY DIFFRACTION	1.2
9H2U	X-RAY DIFFRACTION	1.21
6ZCM	X-RAY DIFFRACTION	1.24
9H2Y	X-RAY DIFFRACTION	1.24
6SZ3	X-RAY DIFFRACTION	1.28
8Q37	X-RAY DIFFRACTION	1.28
9H2W	X-RAY DIFFRACTION	1.28
6YKI	X-RAY DIFFRACTION	1.3
6YNK	X-RAY DIFFRACTION	1.3
6YOQ	X-RAY DIFFRACTION	1.3
7P87	X-RAY DIFFRACTION	1.3
8Q2Q	X-RAY DIFFRACTION	1.3
8Q35	X-RAY DIFFRACTION	1.31
9H2T	X-RAY DIFFRACTION	1.31
8Q31	X-RAY DIFFRACTION	1.32
6T0X	X-RAY DIFFRACTION	1.36
6YNI	X-RAY DIFFRACTION	1.36
8Q2U	X-RAY DIFFRACTION	1.36
8Q4V	X-RAY DIFFRACTION	1.36
8Q4U	X-RAY DIFFRACTION	1.37
6YNO	X-RAY DIFFRACTION	1.4
7PJ8	X-RAY DIFFRACTION	1.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96MU7-F1	60.41	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 361–363; 377–378; 428; 476

Post-translational modifications (14): 35, 118, 120, 146, 148, 308, 315, 317, 318, 320, 424, 435, 545, 96

Mutagenesis-validated functional residues (21):

Position	Phenotype
361	does not affect ability to influence alternative splice site selection.
362	does not affect ability to influence alternative splice site selection.
367	abolished binding to n6-methyladenosine (m6a)-containing rnas.
377	abolishes binding to n6-methyladenosine (m6a)-containing rnas. abolishes binding to m6a-containing mrnas; when associate
377	abolishes rna-binding and ability to influence alternative splice site selection.
380	reduced binding to n6-methyladenosine (m6a)-containing rnas.
387	does not affect ability to influence alternative splice site selection.
399	does not affect ability to influence alternative splice site selection.
401	does not affect ability to influence alternative splice site selection.
402	does not affect ability to influence alternative splice site selection.
409	abolishes rna-binding and ability to influence alternative splice site selection.
411	abolishes rna-binding and ability to influence alternative splice site selection.
428	abolishes binding to n6-methyladenosine (m6a)-containing rnas. abolishes binding to m6a-containing mrnas; when associate
428	does not affect ability to influence alternative splice site selection.
438	reduced binding to n6-methyladenosine (m6a)-containing rnas.
447	does not affect ability to influence alternative splice site selection.
466	does not affect ability to influence alternative splice site selection.
475	reduced binding affinity for n6-methyladenosine (m6a)-containing rnas by 100-fold.
475	does not affect ability to influence alternative splice site selection.
475	reduced binding affinity for n6-methyladenosine (m6a)-containing rnas by 9-fold.
476	does not affect ability to influence alternative splice site selection.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9930044	Nuclear RNA decay

MSigDB gene sets: 274 (showing top): E2F_Q4, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, E2F4DP1_01, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_ALTERNATIVE_MRNA_SPLICING_VIA_SPLICEOSOME, GOZGIT_ESR1_TARGETS_DN, GOBP_OOGENESIS, ATGCAGT_MIR217, TAL1ALPHAE47_01, GOBP_MALE_GAMETE_GENERATION, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, chr4q13, GOBP_NUCLEAR_TRANSPORT, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION

GO Biological Process (14): regulation of alternative mRNA splicing, via spliceosome (GO:0000381), mRNA splicing, via spliceosome (GO:0000398), in utero embryonic development (GO:0001701), mRNA splice site recognition (GO:0006376), mRNA export from nucleus (GO:0006406), spermatogenesis (GO:0007283), dosage compensation by inactivation of X chromosome (GO:0009048), post-transcriptional regulation of gene expression (GO:0010608), regulation of mRNA splicing, via spliceosome (GO:0048024), primary follicle stage (GO:0048160), brown fat cell differentiation (GO:0050873), mRNA alternative polyadenylation (GO:0110104), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (5): RNA binding (GO:0003723), mRNA binding (GO:0003729), molecular sequestering activity (GO:0140313), N6-methyladenosine-containing RNA reader activity (GO:1990247), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), plasma membrane (GO:0005886), nuclear speck (GO:0016607)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
RNA binding	2
alternative mRNA splicing, via spliceosome	1
regulation of mRNA splicing, via spliceosome	1
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
chordate embryonic development	1
spliceosomal complex assembly	1
protein-RNA complex assembly	1
RNA export from nucleus	1
gene expression	1
mRNA transport	1
developmental process involved in reproduction	1
male gamete generation	1
sex-chromosome dosage compensation	1
heterochromatin formation	1
regulation of gene expression	1
mRNA splicing, via spliceosome	1
regulation of RNA splicing	1
regulation of mRNA processing	1
mammalian oogenesis stage	1
fat cell differentiation	1
mRNA 3’-end processing	1
mRNA metabolic process	1
nucleic acid binding	1
molecular_function	1
protein-RNA adaptor activity	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
membrane	1
cell periphery	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

1846 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
YTHDC1	SRSF3	P23152	994
YTHDC1	SRSF10	O75494	979
YTHDC1	KDM3B	Q7LBC6	956
YTHDC1	METTL3	Q86U44	951
YTHDC1	METTL14	Q9HCE5	949
YTHDC1	ZC3H13	Q5T200	934
YTHDC1	CPSF6	Q16630	925
YTHDC1	HNRNPA2B1	P22626	924
YTHDC1	WTAP	Q15007	921
YTHDC1	HNRNPC	P07910	921
YTHDC1	ALKBH5	Q6P6C2	918
YTHDC1	NXF1	Q9UBU9	917
YTHDC1	YTHDF1	Q9BYJ9	912
YTHDC1	VIRMA	Q69YN4	909
YTHDC1	IGF2BP1	Q9NZI8	907

IntAct

229 interactions, top by confidence:

A	B	Type	Score
CLK2	YTHDC1	psi-mi:“MI:0915”(physical association)	0.780
SDCBP2	YTHDC1	psi-mi:“MI:0915”(physical association)	0.780
YTHDC1	SDCBP2	psi-mi:“MI:0915”(physical association)	0.780
KHDRBS3	YTHDC1	psi-mi:“MI:0915”(physical association)	0.720
YTHDC1	RBMY1F	psi-mi:“MI:0915”(physical association)	0.720
YTHDC1	KHDRBS2	psi-mi:“MI:0915”(physical association)	0.720
YTHDC1	DVL3	psi-mi:“MI:0915”(physical association)	0.720
RBMY1F	YTHDC1	psi-mi:“MI:0915”(physical association)	0.720
KHDRBS2	YTHDC1	psi-mi:“MI:0915”(physical association)	0.720
DVL3	YTHDC1	psi-mi:“MI:0915”(physical association)	0.720
HNRNPK	YTHDC1	psi-mi:“MI:0915”(physical association)	0.670
YTHDC1	HNRNPK	psi-mi:“MI:0915”(physical association)	0.670
TRA2B	YTHDC1	psi-mi:“MI:0915”(physical association)	0.670

BioGRID (502): YTHDC1 (Two-hybrid), YTHDC1 (Two-hybrid), YTHDC1 (Two-hybrid), YTHDC1 (Two-hybrid), YTHDC1 (Two-hybrid), RBMY1F (Two-hybrid), KHDRBS2 (Two-hybrid), YTHDC1 (Affinity Capture-MS), YTHDC1 (Affinity Capture-MS), YTHDC1 (Affinity Capture-MS), YTHDC1 (Affinity Capture-MS), YTHDC1 (Affinity Capture-MS), YTHDC1 (Affinity Capture-MS), YTHDC1 (Affinity Capture-MS), SRC (Affinity Capture-Western)

ESM2 similar proteins: A2AR02, A6QLS2, B0BN49, B5DE93, D2H526, E1BB50, E9Q5K9, E9Q784, O35986, O55035, O74418, P30414, P30415, Q13427, Q14AX6, Q19QU3, Q27450, Q3KPW4, Q3MJK5, Q3UC65, Q4R626, Q4V8I5, Q4V9W2, Q505I5, Q5BKY9, Q5R580, Q5R8J6, Q5RJP9, Q5T200, Q5U2S0, Q5VTL8, Q5XHJ5, Q5ZLM8, Q6AXY7, Q6P7Y3, Q7L4I2, Q80SY5, Q8N9E0, Q8N9Q2, Q8R0F5

Diamond homologs: A0A1P8AS03, E7F1H9, E9Q5K9, F4K1Z0, G4MRQ6, P59326, Q06390, Q0VCZ3, Q3MK94, Q4R5D9, Q5RFL8, Q7Z739, Q8BYK6, Q91YT7, Q96MU7, Q9BYJ9, Q9LJE5, Q9QY02, Q9VBZ5, Q9VZQ1, Q9Y5A9, A0A9P4XWM4, A6NMK7, A9LNK9, B2RR83, P0CS64, P0CS65, Q06102, Q0DA50, Q2URI6, Q4IPA4, Q4P384, Q4WKD9, Q59T36, Q5BGN2, Q5R746, Q6BTT1, Q6C922, Q6CKU1, Q6FTL0

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ABL1	down-regulates	YTHDC1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 170 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	9	31.1×	2e-10
mRNA 3’-end processing	14	25.1×	1e-14
RNA Polymerase II Transcription Termination	12	24.0×	2e-12
Transport of Mature mRNA derived from an Intron-Containing Transcript	15	20.8×	2e-14
Processing of Capped Intron-Containing Pre-mRNA	25	18.7×	4e-23
mRNA Splicing	18	18.0×	4e-16
mRNA Polyadenylation	22	17.6×	1e-19
mRNA Splicing - Major Pathway	29	14.4×	2e-23

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	8	40.6×	1e-09
regulation of alternative mRNA splicing, via spliceosome	18	29.1×	2e-19
alternative mRNA splicing, via spliceosome	5	22.3×	2e-04
positive regulation of mRNA splicing, via spliceosome	6	21.6×	3e-05
mRNA splicing, via spliceosome	25	15.2×	9e-20
regulation of RNA splicing	10	14.5×	2e-07
mRNA transport	7	12.2×	1e-04
mRNA export from nucleus	6	11.8×	7e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	60
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2246 predictions. Top by Δscore:

Variant	Effect	Δscore
4:68314319:TCATG:T	acceptor_gain	1.0000
4:68314320:CA:C	acceptor_gain	1.0000
4:68314320:CATG:C	acceptor_gain	1.0000
4:68314320:CATGC:C	acceptor_loss	1.0000
4:68314321:A:C	acceptor_gain	1.0000
4:68314321:ATG:A	acceptor_gain	1.0000
4:68314322:TG:T	acceptor_gain	1.0000
4:68314322:TGCT:T	acceptor_loss	1.0000
4:68314323:GCT:G	acceptor_loss	1.0000
4:68314324:C:CC	acceptor_gain	1.0000
4:68314324:CT:C	acceptor_loss	1.0000
4:68316310:TTA:T	donor_loss	1.0000
4:68316312:A:AC	donor_gain	1.0000
4:68316312:ACTAC:A	donor_loss	1.0000
4:68316313:C:CA	donor_loss	1.0000
4:68316313:C:CC	donor_gain	1.0000
4:68316313:CT:C	donor_gain	1.0000
4:68316313:CTA:C	donor_gain	1.0000
4:68316313:CTACT:C	donor_gain	1.0000
4:68316324:T:C	donor_gain	1.0000
4:68316332:T:C	donor_gain	1.0000
4:68316444:GGGGG:G	acceptor_gain	1.0000
4:68316445:GGGG:G	acceptor_gain	1.0000
4:68316446:GGG:G	acceptor_gain	1.0000
4:68316447:GG:G	acceptor_gain	1.0000
4:68316449:C:CC	acceptor_gain	1.0000
4:68318522:T:A	donor_gain	1.0000
4:68318582:C:CC	acceptor_gain	1.0000
4:68318725:ATCGT:A	acceptor_gain	1.0000
4:68318726:TCGT:T	acceptor_gain	1.0000

AlphaMissense

4772 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:68314283:G:A	T667I	1.000
4:68314292:A:G	L664P	1.000
4:68314292:A:T	L664H	1.000
4:68314294:G:C	F663L	1.000
4:68314294:G:T	F663L	1.000
4:68314295:A:C	F663C	1.000
4:68314295:A:G	F663S	1.000
4:68314296:A:G	F663L	1.000
4:68314301:T:A	D661V	1.000
4:68322875:A:G	F492S	1.000
4:68322883:A:C	C489W	1.000
4:68322884:C:T	C489Y	1.000
4:68322885:A:G	C489R	1.000
4:68322887:A:G	L488P	1.000
4:68322887:A:T	L488H	1.000
4:68322896:C:T	G485E	1.000
4:68322897:C:G	G485R	1.000
4:68322897:C:T	G485R	1.000
4:68324139:C:A	Q478H	1.000
4:68324139:C:G	Q478H	1.000
4:68324140:T:G	Q478P	1.000
4:68324143:C:A	G477V	1.000
4:68324143:C:T	G477E	1.000
4:68324144:C:G	G477R	1.000
4:68324144:C:T	G477R	1.000
4:68324145:A:C	D476E	1.000
4:68324145:A:T	D476E	1.000
4:68324146:T:A	D476V	1.000
4:68324146:T:C	D476G	1.000
4:68324146:T:G	D476A	1.000

dbSNP variants (sampled 300 via entrez): RS1000006100 (4:68320322 T>C), RS1000119963 (4:68319757 T>C), RS1000245662 (4:68313438 G>A), RS1000309499 (4:68349511 C>A), RS1000336601 (4:68327001 C>T), RS1000374832 (4:68350319 A>G), RS1000407561 (4:68350050 T>C,G), RS1000476282 (4:68322574 T>C,G), RS1000587356 (4:68315040 C>A,T), RS1000597198 (4:68311376 T>A,C), RS1000650848 (4:68310366 T>C), RS1000689306 (4:68345572 G>C), RS1000760299 (4:68351710 T>C), RS1000835298 (4:68339203 C>T), RS1000891604 (4:68344023 T>A,C)

Disease associations

OMIM: gene MIM:617283 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
autism spectrum disorder	Limited	Autosomal dominant

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001762_640	Obesity-related traits	3.000000e-06
GCST90002390_209	Mean corpuscular hemoglobin	7.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5169187 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 13,237 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL51085	EBSELEN	3	13,237

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — N6-methyladenosine readers

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
YTHDC1 inhibitor 40	Binding	7.31	pKd

ChEMBL bioactivities

37 potent at pChembl≥5 of 52 total, top 37 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.13	IC50	7.4	nM	CHEMBL5598203
7.53	Kd	29.6	nM	CHEMBL5598203
7.31	Kd	49	nM	CHEMBL5542345
6.84	Kd	146	nM	CHEMBL5532185
6.75	IC50	180	nM	CHEMBL5542401
6.46	IC50	350	nM	CHEMBL5542345
6.35	IC50	450	nM	CHEMBL5559384
6.34	IC50	460	nM	CHEMBL5560295
6.29	IC50	510	nM	CHEMBL5558687
6.23	IC50	590	nM	CHEMBL5557360
6.06	IC50	870	nM	CHEMBL5549847
6.02	IC50	960	nM	CHEMBL5557457
6.01	IC50	970	nM	CHEMBL5556692
6.00	IC50	1000	nM	CHEMBL5527841
6.00	IC50	1000	nM	CHEMBL5563936
6.00	IC50	1000	nM	CHEMBL5527920
6.00	IC50	1000	nM	CHEMBL5568150
5.80	IC50	1600	nM	EBSELEN
5.78	Kd	1680	nM	CHEMBL5177286
5.77	Kd	1700	nM	CHEMBL5177286
5.70	IC50	2000	nM	CHEMBL5532185
5.70	IC50	2000	nM	CHEMBL5559318
5.70	IC50	2000	nM	CHEMBL5550035
5.70	IC50	2000	nM	CHEMBL5562754
5.70	IC50	2000	nM	CHEMBL5560723
5.70	IC50	2000	nM	CHEMBL5565834
5.70	IC50	2000	nM	CHEMBL5567127
5.70	IC50	2000	nM	CHEMBL5563401
5.70	IC50	2000	nM	CHEMBL5558089
5.52	IC50	3000	nM	CHEMBL5518138
5.52	IC50	3000	nM	CHEMBL5563770
5.40	IC50	4000	nM	CHEMBL5563294
5.26	IC50	5500	nM	CHEMBL4436895
5.22	IC50	6000	nM	CHEMBL5559146
5.10	IC50	8000	nM	CHEMBL5558242
5.05	IC50	9000	nM	CHEMBL5558909
5.05	IC50	9000	nM	CHEMBL5558762

PubChem BioAssay actives

37 with measured affinity, of 82 total; 33 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[6-(1,3-thiazol-5-yl)-3-pyridinyl]-4-[2-(trifluoromethyl)benzoyl]-1H-pyrrole-2-carboxamide	2119517: Inhibition of YTHDC1 (unknown origin) by HTRF assay	ic50	0.0074	uM
5-chloro-3-[(3-chlorophenyl)methyl]-N-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-amine;hydrochloride	2072548: Binding affinity to YTHDC1 (unknown origin) assessed as equilibrium dissociation constant by ITC analysis	kd	0.0490	uM
5-chloro-N,3-dimethyl-2H-pyrazolo[4,3-d]pyrimidin-7-amine	2072548: Binding affinity to YTHDC1 (unknown origin) assessed as equilibrium dissociation constant by ITC analysis	kd	0.1460	uM
3-chloro-5-[[2-chloro-6-(methylamino)purin-9-yl]methyl]benzoic acid	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	0.1800	uM
N-[4-chloro-2-[[2-chloro-6-(methylamino)purin-9-yl]methyl]phenyl]methanesulfonamide	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	0.4500	uM
N-[2-[[2-chloro-6-(methylamino)purin-9-yl]methyl]phenyl]methanesulfonamide	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	0.4600	uM
3-[[2-chloro-6-(methylamino)purin-9-yl]methyl]benzoic acid	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	0.5100	uM
2-chloro-9-[(3-chloro-4-methoxyphenyl)methyl]-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	0.5900	uM
4-[[2-chloro-6-(methylamino)purin-9-yl]methyl]benzoic acid	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	0.8700	uM
2-chloro-9-[(3-chlorophenyl)methyl]-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	0.9600	uM
methyl 4-[[2-chloro-6-(methylamino)purin-9-yl]methyl]benzoate	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	0.9700	uM
2-chloro-N-methyl-9-[[3-(2H-tetrazol-5-yl)phenyl]methyl]purin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	1.0000	uM
methyl 3-[[2-chloro-6-(methylamino)purin-9-yl]methyl]benzoate	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	1.0000	uM
3-[[2-chloro-6-(methylamino)purin-9-yl]methyl]-N-methylbenzamide	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	1.0000	uM
methyl 3-chloro-5-[[2-chloro-6-(methylamino)purin-9-yl]methyl]benzoate	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	1.0000	uM
2-phenyl-1,2-benzoselenazol-3-one	2119516: Inhibition of YTHDC1 (unknown origin)	ic50	1.6000	uM
N,3-dimethyl-2H-pyrazolo[4,3-d]pyrimidin-7-amine	2072547: Binding affinity to YTHDC1 (unknown origin) assessed as dissociation constant	kd	1.6800	uM
9-[(3-chlorophenyl)methyl]-2-fluoro-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	2.0000	uM
2-chloro-9-[[2-(difluoromethyl)phenyl]methyl]-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	2.0000	uM
3-[[2-chloro-6-(methylamino)purin-9-yl]methyl]benzamide	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	2.0000	uM
[4-[[2-chloro-6-(methylamino)purin-9-yl]methyl]phenyl]methanol	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	2.0000	uM
3-[[2-chloro-6-(methylamino)purin-9-yl]methyl]benzonitrile	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	2.0000	uM
N-[2-[[2-chloro-6-(methylamino)purin-9-yl]methyl]phenyl]-4-methylbenzenesulfonamide	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	2.0000	uM
9-[(3-bromophenyl)methyl]-2-chloro-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	2.0000	uM
2-chloro-9-[(3,5-dichloro-4-methoxyphenyl)methyl]-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	2.0000	uM
2-chloro-N-methyl-9-[[2-(trifluoromethyl)phenyl]methyl]purin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	3.0000	uM
9-benzyl-2-chloro-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	3.0000	uM
2-chloro-9-[(3-methoxyphenyl)methyl]-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	4.0000	uM
4-(2-bromo-6-fluorobenzoyl)-N-pyridin-3-yl-1H-pyrrole-2-carboxamide	2119516: Inhibition of YTHDC1 (unknown origin)	ic50	5.5000	uM
2-chloro-N-methyl-9-(pyridin-4-ylmethyl)purin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	6.0000	uM
2-chloro-9-(cyclohexylmethyl)-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	8.0000	uM
2-[2-chloro-6-(methylamino)purin-9-yl]-N-phenylacetamide	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	9.0000	uM
9-[(2-aminophenyl)methyl]-2-chloro-N-methylpurin-6-amine	2072549: Inhibition of GST-tagged YTHDC1 (unknown origin) by HTRF assay	ic50	9.0000	uM

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation	3
sodium arsenite	decreases expression, increases abundance, increases expression	3
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	2
perfluorooctane sulfonic acid	decreases expression	2
Acrolein	increases abundance, affects cotreatment, increases expression	2
Arsenic	increases expression, increases abundance	2
Ozone	affects cotreatment, increases expression, increases abundance	2
Tobacco Smoke Pollution	increases expression	2
Valproic Acid	decreases expression	2
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
2,4,6-tribromophenol	increases expression	1
alpha-pinene	increases abundance, affects cotreatment, increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
arsenite	affects binding, decreases reaction	1
perfluorooctanoic acid	decreases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
coumarin	increases phosphorylation	1
cadmium sulfate	increases expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	decreases expression	1
K 7174	increases expression	1
perfluorohexanesulfonic acid	decreases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	decreases expression	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5149945	Binding	Binding affinity to GST-tagged YTHDC1 m6A-reader domain (unknown origin) assessed as residual signal level using RRACH-containing methylated oligoRNA at 1 mM incubated for 3 hrs by HTRF assay	Fragment Ligands of the m6A-RNA Reader YTHDF2. — ACS Med Chem Lett

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder